Research Analysts Set Expectations for DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Equities researchers at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Bright Minds Biosciences in a report issued on Wednesday, July 2nd. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($2.35) per share for the year, down from their previous forecast of ($0.64). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Bright Minds Biosciences' current full-year earnings is ($1.24) per share. Cantor Fitzgerald also issued estimates for Bright Minds Biosciences' FY2026 earnings at ($7.34) EPS.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.10.

A number of other equities analysts have also commented on the company. Wall Street Zen lowered Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Chardan Capital reiterated a "buy" rating and issued a $80.00 price objective on shares of Bright Minds Biosciences in a report on Wednesday, May 21st. TD Cowen started coverage on Bright Minds Biosciences in a report on Tuesday, May 13th. They issued a "buy" rating for the company. Finally, Cowen initiated coverage on Bright Minds Biosciences in a report on Tuesday, May 13th. They issued a "buy" rating for the company. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $83.25.

Bright Minds Biosciences Trading Down 3.1%

DRUG stock traded down $0.88 during trading on Friday, hitting $27.50. The company had a trading volume of 2,425 shares, compared to its average volume of 825,787. The company has a fifty day moving average price of $29.00 and a two-hundred day moving average price of $33.40. The company has a market cap of $193.56 million, a P/E ratio of -76.37 and a beta of -6.01. Bright Minds Biosciences has a fifty-two week low of $0.93 and a fifty-two week high of $79.02.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE acquired a new stake in Bright Minds Biosciences during the 4th quarter worth approximately $173,000. Jane Street Group LLC bought a new position in shares of Bright Minds Biosciences in the 4th quarter valued at $238,000. OMERS ADMINISTRATION Corp bought a new position in shares of Bright Minds Biosciences in the 1st quarter valued at $505,000. Atika Capital Management LLC acquired a new position in Bright Minds Biosciences in the 4th quarter worth about $540,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Bright Minds Biosciences in the first quarter valued at about $802,000. 40.52% of the stock is owned by institutional investors and hedge funds.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.